Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting

Vertigo Clinical Trial

Official title:

Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04869020
• Other study ID #: Olith10701
• Status: Active, not recruiting
• Phase: N/A
• Start date: May 7, 2021
• Est. completion date: June 2022

Study information

• Verified date: March 2022
• Source: Otolith Labs
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices. The study is designed to be conducted remotely using video conferencing between representatives of the manufacturer of the Otoband and participants. In order to comply with requirements for non-essential contact due to the Covid-19 pandemic there will be no person to person contact in the study.

Description:

In this phase of this pilot study, a minimum of 20 participants will be enrolled, with up to 100 participants maximum. This will provide adequately powered pilot data to measure effect size for the OtoBand and sham devices and to identify different causes of vertigo for which the OtoBand has a particularly strong effect as measured by the Otolith Vertigo Assessment Tool. After inclusion/exclusion screening and informed consent is obtained, potential participants will be assessed using the Dizziness Handicap Inventory (DHI). The DHI will be completed online. Potential participants with a DHI score in the appropriate range will be accepted into the study. These participants will be asked to schedule an online meeting to with the study coordinator. In this online enrollment meeting, the study coordinator will review the Informed Consent and confirm other information supplied by the participant online (inclusion/exclusion) and then make an affirmative decision to enroll or not enroll participants in the study. The participants will be randomly assigned to one of the two arms of the study (OtoBand / Sham Device A or OtoBand / Sham Device B). This is a blinded study in which every participant will be evaluated, and each participant may select the stimulation that best suits him or her on both of the study devices. Each participant will select his/her preferred stimulation level by pressing the power level button on the study device; however, they will be blinded to which device they are using. Study participants will be asked to use the devices whenever they are having a symptom of vertigo. Each participant will be asked to record his/her level of vertigo in the online Study Diary: before putting on the device, after wearing the device for 5 minutes, after removing the device. The study devices will record the following information regarding usage: Date and time when the device is turned on/off and the power level, Date and time when the power level is changed and the new power level. Participants will be allowed to use the device as long as they are getting benefit from the device at any power setting that they select. Participants will be asked to complete an entry in the Study Diary even on days on which they do not experience a vertigo episode. The study coordinator will schedule six study monitoring call with each participant as close as possible to the following schedule: Call 1: Device I: 4 days after enrollment Call 2: Device I: 9 days after enrollment Call 3: Device I: 14 days after enrollment Call 4: Device II: 17 days after enrollment Call 5: Device II: 22 days after enrollment Call 6: Device II: 27 days after enrollment

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 40
• Est. completion date: June 2022
• Est. primary completion date: March 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male or female subjects age 18 to 70 years old
• Vertigo that has been present for at least 90 days
• Vertigo that is constant or predictable
• Consulted a medical doctor in the past 24 months regarding their vertigo
• Identify as having vertigo from one of the following causes:
• Benign Paroxysmal Positional Vertigo (BPPV)
• Meniere's Disease
• Vestibular Migraines
• Migraine Associated Vertigo
• Vestibular Neuritis
• Labyrinthitis
• Vertigo caused by COVID-19
• Score within appropriate range on the Dizziness Handicap Inventory
• Have a computer and access to internet for online video conferences
• PayPal, Venmo or Zelle account to receive compensation

Exclusion Criteria:

• Vertigo that first presented within the last 90 days
• Skull base surgery within the last 90 days
• Any skull implant (cochlear implant, bone conduction implant, DBS)
• Taking benzodiazepines (e.g., clonazepam, lorazepam, diazepam) for dizziness
• Vitreous detachment of the retina (floaters in the eye) in the previous 90 days

Related Conditions & MeSH terms

• Dizziness
• Vertigo

Intervention

Device:
• Otoband
Participants with vertigo will wear the Otoband set at their chosen power level when experiencing symptoms.
• Sham A
Sham Device A is an OtoBand in which the transducer is modified so that the vibrations are not targeted at the vestibular system.
• Sham B
Sham Device B is an OtoBand that operates at power settings found to be nontherapeutic against vertigo associated with virtual reality.

Locations

Country	Name	City	State
United States	Otolith Labs	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Otolith Labs

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in vertigo severity rating while wearing the OtoBand compared to the change in vertigo severity while wearing a sham device.	The primary endpoint will be the change in vertigo severity rating while wearing the OtoBand compared to the change vertigo severity while wearing the sham device during the worst, most intense episode of vertigo within each treatment period (sham versus OtoBand device).	Forms filled out daily over four week period by the study participant
Secondary	Average change in vertigo severity rating while wearing the OtoBand compared to average change in vertigo severity while wearing the sham device.	This secondary outcome measure will be a statistically significant average improvement in reported vertigo when wearing the OtoBand, using the average change in reported vertigo when wearing the sham device as a reference.	Forms filled out daily over four week period by the study participant
Secondary	Frequency of vertigo events during each period of testing (OtoBand versus sham).	We will compare the number of "definite vertigo days" during the study period, comparing the OtoBand period vs the sham period.	Forms filled out daily over four week period by the study participant
Secondary	Durability of the effect over the observation period.	We will compare the mean change in reported vertigo during the first week vs the second week of use, for the period of OtoBand use and the period of sham device use. This will give an indication of whether any potential therapeutic effect of the devices remains constant over the duration of the study.	Forms filled out daily over four week period by the study participant
Secondary	Complaints regarding usage.	We will classify complaints expressed during monitoring visits as "discomfort", "worsening" and those related to "efficacy", and model interactions between time and number of complaints, as a function of the testing group (OtoBand versus sham).	Information gathered in each monitoring visits over the four week period.
Secondary	Relationship of the bone conduction stimulation level (in dB) selected by the participant to severity of reported vertigo.	We will evaluate any relationship between preferred bone conduction stimulation level and severity of vertigo episodes, by modelling interactions between time and (mean) bone conduction stimulation level selected by the participant for each vertigo episode, as a function of the testing group (OtoBand versus sham).	Forms filled out daily by the study participant over four week period compared to two data files captured by the devices over their two week usage.
Secondary	Duration of use within each episode of vertigo and over the entire observation period.	We will evaluate any change in vertigo episode duration, by modelling interactions between time (day) and duration of device use per episode, as a function of the testing group (OtoBand versus sham).	Forms filled out daily over four week period by the study participant
Secondary	Identification of a preferred dose.	We will measure the mean preferred power level per reported condition (BPPV, vestibulopathy, Meniere, Migraine associated vertigo) over all participants.	Data captured by the devices over the 14 days with each device.
Secondary	Identification of the sham device with the smallest placebo effect.	We will measure any potential effectiveness of the sham devices, by comparing the mean change in vertigo score with the OtoBand and with the sham, for each of the two sham devices.	Forms filled out daily over 2 week period by the study participant with the sham in each arm.